Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia.The overall objective of the study is to compare the efficacy and safety of combining fenofibrate and simvastatin versus pravastatin monotherapy in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
423
Combination of Fenofibrate and Simvastatin 20mg
Combination of Fenofibrate and Simvastatin 40 mg
Pravastatin 40 mg
Percent change from baseline to 12 weeks of treatment in Triglycerides
Time frame: 12 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C
Time frame: 12 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C
Time frame: 12 weeks
Percent change from baseline to 12 weeks of treatment in Triglycerides
Time frame: 24 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C
Time frame: 24 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site 40
Athens, Greece
Site 39
Ioannina, Greece
Site 41
Thessaloniki, Greece
Site 37
Beer Yaakov, Israel
Site 19
Haifa, Israel
Site 22
Holon, Israel
Site 18
Jerusalem, Israel
Site 38
Kfar Saba, Israel
Site 17
Ramat Gan, Israel
Site 21
Ramat Gan, Israel
...and 31 more locations